Navigating the Road to Adherence Imagine this: you’ve been given a luxury sports car to drive with no steering wheel, only an ignition button. In the glovebox, there is an… Read More »
Biologic drugs are finding growing success in addressing chronic diseases — from diabetes and rheumatoid arthritis to multiple sclerosis and Crohn’s. A significant rise in self-injection therapies is contributing to… Read More »
We speak with Adam Shain, Director Business Development, Digital Healthcare, and Josh Hopkins, Program Manager, AdhereIT about the AdhereIT 360 Base and AdhereIT Clip – a runner up for The… Read More »
The biopharmaceutical industry has experienced incredible exponential growth in recent decades. Annual revenues have increased from US$4.4 billion (£3.4 billion) in 1990 to $275 billion (£213 billion) in 2018 (a… Read More »
With more biologics and drug delivery device options entering the market in recent years, pharma companies can decide whether it would be easier for patients to self-inject with an autoinjector… Read More »
Diagnoses of chronic illnesses such as rheumatoid arthritis (RA), Crohn’s disease and osteoporosis are expected to skyrocket in the coming decade, resulting in growing use of patient-centric drug delivery devices… Read More »